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Cardiomyopathies can result from mutations in genes encoding sarcomere proteins including MYBPC3, which encodes cardiac
myosin binding protein-C (cMyBP-C). However, whether oxidative stress is augmented due to contractile dysfunction and
cardiomyocyte damage in MYBPC3-mutated cardiomyopathies has not been elucidated. To determine whether oxidative stress
markers were elevated in MYBPC3-mutated cardiomyopathies, a previously characterized 3-month-old mouse model of dilated
cardiomyopathy (DCM) expressing a homozygous MYBPC3 mutation (cMyBP-C(t/t)) was used, compared to wild-type (WT)
mice. Echocardiography confirmed decreased percentage of fractional shortening in DCM versus WT hearts. Histopathological
analysis indicated a significant increase inmyocardial disarray and fibrosis while the second harmonic generation imaging revealed
disorganized sarcomeric structure and myocyte damage in DCM hearts when compared to WT hearts. Intriguingly, DCMmouse
heart homogenates had decreased glutathione (GSH/GSSG) ratio and increased protein carbonyl and lipid malondialdehyde
content compared to WT heart homogenates, consistent with elevated oxidative stress. Importantly, a similar result was observed
in human cardiomyopathy heart homogenate samples. These results were further supported by reduced signals for mitochondrial
semiquinone radicals and Fe-S clusters in DCM mouse hearts measured using electron paramagnetic resonance spectroscopy. In
conclusion, we demonstrate elevated oxidative stress inMYPBC3-mutated DCM mice, which may exacerbate the development of
heart failure.
1. Introduction
Heart failure (HF) remains a leading cause of morbidity and
mortality worldwide and affects 5.1 million people in the
United States [1]. Cardiomyopathies are a leading cause of HF
and are still associatedwith substantialmorbidity andmortal-
ity despite optimal treatment [2].Therefore, novel therapeutic
targets and treatments are required. Over the past 20 years,
many inherited mutations within genes encoding proteins of
the cardiac sarcomere have been identified as causing dilated
(DCM) and hypertrophic (HCM) cardiomyopathy [2]. The
genetic basis of HCM has been well established with more
than 1400 mutations in genes encoding sarcomeric proteins
having been identified [3, 4]. For example, mutations in
MYBPC3, which encodes the contractile regulatory protein
cardiac myosin binding protein-C (cMyBP-C), are the most
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common cause of HCM accounting for approximately 40%
of the identified mutations [5]. Furthermore, it is estimated
that DCM is triggered by mutations in sarcomeric protein
genes, including MYPBC3, in 35–40% of genetic cases [6].
Due to sarcomere protein mutations, these cardiomyopathies
are typically characterized by severe contractile dysfunction
that worsens over time promoting either cardiac hypertrophy
or dilation, depending on the phenotypic response of the
heart to themutation [7].These responses involve progressive
myocardial remodeling that includes myocyte disarray and
damage that may lead to increased cardiac oxidative stress.
A previous study by Marian et al., using a genetic mouse
model of HCM caused by mutation of cardiac troponin
T (cTnT), examined the pathogenesis of interstitial fibrosis
in terms of the balance between oxidants and antioxidants
regulating normal collagen homeostasis [8]. Their find-
ings indicated that antioxidant therapy leads to reduced
myocardial oxidative stress and fibrosis [8]. Lombardi et
al. later confirmed this in 𝛽-myosin heavy-chain transgenic
rabbits, which had reversed cardiac myocyte hypertrophy
and interstitial fibrosis with a reduction in oxidized to total
glutathione ratio upon antioxidant therapy, indicating the
potential benefit of antioxidant therapy in the treatment of
human HCM [9]. Recently, Lu et al. have demonstrated that
cardiac oxidative stress is elevated in the cTnTR141W mouse
model of DCM, which is inhibited by knockdown of CYP2E1
leading to an improved cardiac phenotype [10]. However,
whether oxidative stress results from tissue damage caused
by contractile dysfunction and myocardial remodeling in
sarcomere protein-mutated forms of cardiomyopathy other
than by cTnT mutation requires further elucidation.
In this study, we use a well-characterized mouse model of
genetic DCM (cMyBP-C(t/t)) having a homozygousMYBPC3
sarcomere gene mutation that produces truncated cMyBP-C
variant [11–14] and heart tissue from human cardiomyopathy
patients for comparison.We tested whether oxidative stress is
elevated in cardiomyopathies caused by MYBPC3 mutation
and if this corresponds to worsened cardiac function and
increased myocyte damage. Our data extend previous find-
ings in models of HCM and DCM to include DCM caused
by MYBPC3 mutations as having elevated oxidative stress
that corresponded to severe cardiac dysfunction, myocyte
damage, and myocardial remodeling.
2. Materials and Methods
2.1. Patients. For human studies, the investigation conformed
to the principles outlined in the Declaration of Helsinki.
The IRB at Loyola University Chicago approved the present
study using the deidentified human heart tissue samples
(LU number 205840). Human heart samples used here were
from the Sydney Heart Bank and were collected under
HREC approvals from theUniversity of Sydney (HREC num-
ber 2814) and from St. Vincent’s Hospital (HREC number
H91/048/1a). The cardiomyopathy patient group consisted
of 10 men and 4 women. Mean patient age was 43.3 ± 14.1
years. The donor group consisted of 9 men and 4 women
with no known cardiovascular disease. Mean patient age was
43.5 ± 12.3 years. Detailed patient clinical characteristics are
provided in Table 1.
2.2. Mouse Model of DCM. A knock-in mouse model of
DCM [11], in which a homozygous mutation in MYBPC3
causes a C󸀠-modified cMyBP-C (cMyBP-C(t/t)) that does not
incorporate into sarcomeres resulting in a cMyBP-C null
heart [11], and age matched wild-type (WT) mice (FVB/N)
were used to determine the association between oxidative
stress, cardiac function, and myocardial remodeling in sar-
comere protein-mutated DCM. Male and female WT and
cMyBP-C(t/t) animals were used for these studies. All animal
protocolswere approved by the InstitutionalAnimalCare and
Use Committee at Loyola University Chicago (LU number
205109) and were in accordance with the guidelines listed
in the Guide for the Use and Care of Laboratory Animals
published by the National Institutes of Health. Prior to organ
harvesting, animals were euthanized in a carbon dioxide
(CO2) chamber by slow flow of CO2 (10–30% of chamber
volume per minute) followed by continued exposure for 15–
30 minutes after breathing had stopped.
2.3. In Vivo Cardiac Function by Noninvasive Echocardiog-
raphy. Cardiac function in WT and DCM mice that were
anesthetized with 2% Isoflurane via inhalation was assessed
by echocardiography using a Vevo 2100 (Fujifilm, Visual
Sonics, Inc., Toronto, Canada) with a MS-550D 22–55MHz
transducer. Left ventricular internal diameter, wall thickness,
and contractile function were measured using parasternal
long-axis M-mode imaging and the Visual Sonics Vevo 2100
analysis package as described previously [12].
2.4. Histopathological Analyses. To assess the gross morphol-
ogy of DCM versus WT hearts, the hearts were removed
from anesthetized mice and were then drained of blood and
fixed in 10% formalin. Hearts were bisected longitudinally
or cross-sectioned at the base and dehydrated with a graded
series of alcohols before being embedded in paraffin. Then,
5 𝜇m step-serial sections were taken from WT and DCM
hearts and stained with hematoxylin and eosin (H&E) or
Masson’s trichrome. The H&E and Masson’s trichrome-
stained sections were imaged using the slide scanning sys-
tem (Nanozoomer RT 2.0, Hamamatsu Corporation, Tokyo,
Japan) using a 20x Uplansapo objective at a resolution of
0.23 𝜇m under bright field mode. To analyze the cellularity
(nuclear area) and fibrosis, high-resolution images were
exported from whole heart scanned sections. Images were
thresholded based on RGB values for either nuclei (using the
H&E labeled sections) or fibrosis (using trichrome-labeled
sections) and the area of pixels occupied by these components
was quantified in the program Axiovision (version 4.8, Carl
Zeiss Microimaging, Jena, Germany).
2.5. Biochemical Measurements of GSH/GSSG Ratio. The
ratio of reduced GSH to oxidized GSH (GSSG) serves as
a marker of oxidative stress and redox status [15, 16]. The
GSH/GSSG ratio was measured in WT and DCM heart
homogenates as well as donor and cardiomyopathy human
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Table 1: Clinical patient characteristics.
Patients Sex Age Clinical information
1 M 31 NYHA IV, severe ischemia
2 M 43 Unknown
3 M 56 Right ventricular heart failure, Uhl’s syndrome, severe right ventriculardysplasia, tricuspid regurgitation, and thin IVS
4 M 54 Severe nonobstructive hypertrophic cardiomyopathy, homozygous TNNTmutant, and triple bypass
5 F 47
Automatic implantable cardioverter-defibrillator, atrial fibrillation,
hypothyroid, sinus rhythm, left ventricular hypertrophy, LVEF 20–30%,
NYHAII/III, and fractional shortening 21%
6 F 57 Defibrillator, septal hypertrophy, LVEF 15%, and NYHA III
7 F 41 Automatic implantable cardioverter-defibrillator, dual pacemaker, LVEF50%, and NYHA IV
8 M 61 Atrial fibrillation, LVEF 30%, and NYHA III/IV
9 M 32 HOCM, IVS = 23mm, and LVOT pressure gradient = 88mmHg
10 M 60 HOCM, IVS = 23mm, and LVOT pressure gradient = 77mmHg
11 F 24 HOCM, IVS = 24mm, and LVOT pressure gradient = 81mmHg
12 M 33 HOCM, IVS = 21mm, and LVOT pressure gradient = 59mmHg
13 M 17 HOCM
14 M 50 HOCM
Donors Sex Age Cause of death
1 M 56 Hypoxia (hanged)
2 M 45 Unknown
3 M 48 Intracranial hemorrhage, cardiac arrest 23 minutes
4 F 42 Multiple sclerosis, Guillain Barre´ syndrome
5 F 62 Hypoxia (hanged)
6 F 47 Poland syndrome, hydrocephalus, cardiac arrested 35min, and celsiorcardioplegia
7 M 28 Poland syndrome, hydrocephalus, cardiac arrested 35min, and celsiorcardioplegia
8 M 62 Middle cerebral artery aneurism and hemorrhage, brain herniation
9 F 49 Unknown
10 M 40 Unknown
11 M 29 Unknown
12 M 25 Unknown
13 M 33 Unknown
HOCM = hypertrophic obstructive cardiomyopathy, IVS = interventricular septum, LVEF = left ventricular ejection fraction, LVOT = left ventricular outflow
tract, and NYHA = New York Heart Association class.
heart tissue homogenates using Cayman’s GSH assay kit
(Cayman Chemical, Cat. number 703002) as per the man-
ufacturer’s instructions. To prepare tissue homogenate, iso-
lated hearts from WT and cMyBP-C(t/t) mice were perfused
with PBS (pH 7.4) prior to dissection to remove red blood
cells and clots and a freeze clamp was used to freeze the
tissue. Heart tissue from WT and DCM mice, as well as
from donor and cardiomyopathy patients, was homogenized
in cold buffer (phosphate, pH 6-7, and 1mM EDTA) and
centrifuged at 10,000×g for 15 minutes at 4∘C. Samples were
deproteinated with equal volumes of metaphosphoric acid
(MPA, Sigma-Aldrich number 239275), vortexed, allowed to
stand at room temperature for 5 minutes, and centrifuged
at >2,000 g for 2 minutes. Supernatant was collected and
stored at −20∘C. To assay total GSH (oxidized and reduced
forms), 4M triethanolamine (TEAM, Sigma-Aldrich number
T58300) was added to the supernatant, which was then
vortexed. To quantify GSSG independent of GSH, 1M 2-
vinylpyridine (Sigma-Aldrich number 13229-2) in ethanol
was added to deproteinated serum. Samples were mixed and
incubated at room temperature for 60 minutes. Total GSH
or GSSG levels were determined by adding the samples into
wells of a 96-well plate. An assay cocktail containing MES
buffer, reconstituted CofactorMixture, reconstituted Enzyme
Mixture, water, and reconstituted DTNB was added to the
sample wells.The plate was covered and incubated in the dark
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on an orbital shaker. Absorbance in the wells was read at
405 nm at 5-minute intervals for 30minutes using the BioTek
Epoch microplate reader. The data were analyzed using the
Gen5 5.1.11 Data Analysis Software (BioTek).
2.6. Protein Carbonyl Assay. Carbonyl groups (aldehydes
and ketones) are produced from the oxidation of protein
side chains [17]. They react with 2,4-dinitrophenylhydrazine
(DNPH) generating protein-bound 2,4-dinitrophenylhydra-
zones, which can be quantitated spectrophotometrically [18].
Therefore, protein carbonyl content serves as a general
indicator of protein oxidation, oxidative stress, and oxidative
damage [17, 18]. Protein carbonyl content was determined
in WT and DCM heart tissue homogenates and in donor
and cardiomyopathy human heart tissue homogenates using
Cayman’s Protein Carbonyl Colorimetric Assay Kit (Cay-
man Chemical, Cat. number 10005020) as per the man-
ufacturer’s instructions. Tissue was homogenized in cold
buffer (50mM MES or phosphate buffer pH 6.7 containing
1mM EDTA) and centrifuged at 10,000×g for 15min at 4∘C.
Sample and control tubes were prepared by adding 200 𝜇L
of supernatants from centrifuged tissue samples into two
tubes (sample and control) followed by addition of 800 𝜇L
of 2,4-dinitrophenylhydrazine (DNPH) to the sample tube
and 800 𝜇L of 2.5M HCL to the control tube. Both tubes
were incubated in the dark for 60min at room tempera-
ture with 15min intermittent vortexing. Then, 1mL of 20%
trichloroacetic acid (TCA) was added to each of the tubes,
which were vortexed and incubated on ice for 5min. Samples
were centrifuged at 10,000×g for 10 minutes at 4∘C and the
supernatant was discarded. Pellets were resuspended in 10%
TCA and incubated on ice for 5min. The samples were cen-
trifuged as above and the supernatants were discarded. The
pellets were washed with 1mL of a 1 : 1 ethanol : ethyl acetate
mixture. Then, the pellets were resuspended, vortexed, and
centrifuged as above. The washing procedure was performed
two more times. Finally, the pellets were resuspended in
500𝜇L guanidine hydrochloride by vortexing and were cen-
trifuged as above to remove debris. The amount of protein-
hydrazone produced was quantified spectrophotometrically
at 360 nm. The carbonyl content was then normalized to
protein concentration.
2.7. Lipid Peroxidation Assay. The oxidation of polyun-
saturated fatty acids generates reactive carbonyl com-
pounds including the aldehydic compounds malondialde-
hyde (MDA) and 4-hydroxyalkenal (HAE), which have been
used as markers of lipid peroxidation and oxidative damage
[19, 20].MDA+HAEcontentwasmeasured inWTandDCM
mouse heart tissue homogenates and in donor and cardiomy-
opathy human heart tissue homogenates by a lipid peroxida-
tion colorimetric assay (Oxford Biochemical Research, Prod-
uct number FR 12) as per the manufacturer’s instructions.
Tissues were homogenized in 20mM potassium phosphate
buffer (pH 7.4) containing 0.5M butylated hydroxytoluene
(W218405-1KG-K Sigma). Lysate was clarified by centrifuga-
tion at 3000×g at 4∘C and supernatant was collected in a fresh
tube. Protein concentration was measured using Coomassie-
Plus (Bradford) protein assay (Cat. number 23236 Thermo
Scientific Rockford, IL). The assay was performed by taking
200𝜇L of lysate mixed with 650 𝜇L of diluted R1 reagent (N-
methyl-2-phenylindole in acetonitrile). Samples were gently
mixed by vortexing followed by addition of 150 𝜇L of R2
reagent (methanesulfonic acid [MSA]). Samples were mixed
well and tubes were stoppered and then incubated at 45∘C
for 60min. Turbid samples were centrifuged at 15,000×g for
10min to obtain a clear supernatant. Absorbance at 586 nm
was measured for the supernatant along with the MDA stan-
dards (1,1,3,3-tetramethoxypropane [TMOP] in Tris-HCl).
Separate sample blanks and reagent blanks were used to
subtract the background.The concentration of analyte in each
unknown was calculated from the net 𝐴586 of the sample
using the following formula:
[MDA] =
𝐴586 − 𝑏
𝑎
⋅ df , (1)
where [MDA] is the𝜇Mconcentration ofMDA in the sample,
𝐴586 = net absorbance at 586 nmof the sample, 𝑎 = regression
coefficient (slope), 𝑏 = intercept, and df = dilution factor.
2.8. Electron Paramagnetic Resonance (EPR) Spectroscopy.
EPR spectroscopic analysis was used to measure the free
radical and paramagnetic species. The excised heart tis-
sues were flash frozen and stored in liquid nitrogen for
EPR spectroscopic analysis to measure the free radical and
paramagnetic species. Each EPR sample was prepared by
transferring the frozen heart tissue (160–270mg) into a
ceramic mortar prechilled with liquid nitrogen [21]. The
tissue was then broken into small pieces in liquid nitrogen
using a pestle.The tissue was then loaded into a finger Dewar
containing liquid nitrogen. Low temperature, 77 K, and EPR
spectra were recorded with a Bruker ESP 300E spectrometer
(Bruker BioSciences, Billerica, MA, USA) operating at X-
band with 100 kHzmodulation frequency and a TM110 cavity
as described previously [21]. The finger Dewar containing
heart tissue samples in liquid nitrogen was placed within
the EPR spectrometer cavity. All spectra were recorded with
the following parameters: microwave frequency = 9.45GHz,
modulation amplitude = 5G (2G for semiquinone radical
signals), time constant = 164ms, scan time = 60 s, microwave
power = 20mW (1mW for semiquinone radicals), and num-
ber of scans = 10. After this experiment, the heart tissue
samples were used for the measurement of reactive oxygen
species (ROS) formation. The EPR spin probe 1-hydroxy-3-
carboxymethyl-2,2,5,5-tetramethyl-pyrrolidine (CMH, EPR
silent) is oxidized by ROS and peroxynitrite (OONO−) to
3-carboxymethyl-2,2,5,5-tetramethyl-pyrrolidinyloxy radical
(CM∙, EPR active) [22]. Heart tissues (50mg) were treated
with spin probe CMH (Alexis Biochemicals/Enzo Life Sci-
ences) (1mM) in Krebs buffer containing deferoxamine
mesylate (Sigma-Aldrich) (25𝜇M) and incubated at 37∘C in a
water bath for 30 minutes.The supernatant was collected and
used for the CM∙ analysis. Samples were loaded into capillary
tubes and EPR spectra were recorded at room tempera-
ture using a Bruker X-band EMX premiumX spectrometer.
The following acquisition parameters were used: microwave
power, 20mW; modulation frequency, 100 kHz; modulation
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amplitude, 0.5 G; time constant, 82ms; scan time, 41 s; and
number of scans, 1.
2.9. SecondHarmonicGeneration Imaging (SHG) of Sarcomere
Pattern and FFT Analysis. SHG imaging of myosin complex
in representative WT and DCM hearts was accomplished
and quantified as described previously [23–25]. The myosin
complexwas imagedwithout any labeling using the scattering
process of sarcomere in forward directed SHG signals and
the fibrous collagen was picked up by the backward directed
SHG signals [25] using the H&E labeled whole hearts. All
imaging, including the autofluorescence of tissue sections
together with SHG signals, was performed using the LSM 710
confocalmicroscope equippedwith nondescanned detectors.
The excitation was 780 nm by two-photon laser and the
detection bands are 380–400 nm as the scatters are exactly
twice the frequency of excitation.The autofluorescence of the
tissues was detected simultaneously between 600 and 650 nm
[25]. The integrity of sarcomere pattern was analyzed using
the Fast Fourier Transformation analysis in the program
Fiji [26]. In addition, the loss of sarcomere pattern was
analyzed using line intensity profiles measurement, which
reveals fine structure by showing peaks whenever the fine
structure is present. If not, these intensity profileswere devoid
of peaks (flat lines). These intensity profiles are made using
the aforementioned Axiovision program (version 4.8, Carl
Zeiss Microimaging, Jena, Germany).
2.10. Statistical Analysis. Data are represented asmean values
± SEM. Significant differences between mean values were
determined using Student’s 𝑡-test. Statistically significant
differences were considered as 𝑃 < 0.05.
3. Results
3.1. DCM Hearts Display Contractile Dysfunction, Fibrosis,
and Myocardial Disarray. Hearts from the cMyBP-C(t/t)
genetic mouse model of DCM have previously been charac-
terized as having increased LV diastolic and systolic diameter
and reduced LV fractional shortening (FS) suggestive of a
DCM phenotype [11]. To confirm the presence of DCM in
the cMyBP-C(t/t)mice used here, we implemented parasternal
long-axis M-mode echocardiography and assessed cardiac
function in these animals compared to WT animals (Fig-
ure 1(a)). DCM animals had a significant elevation in LVID at
both peak diastole (Figure 1(b)) and peak systole (Figure 1(c))
indicating dilation of the LV chamber. No significant differ-
ence was observed in total wall thickness in the hearts of WT
and DCM animals (data not shown). However, we found a
significant reduction in ejection fraction (EF) (Figure 1(d))
and FS (Figure 1(e)) in DCM hearts compared to WT hearts
signifying impaired cardiac function in DCM hearts.
McConnell et al. previously characterized homozygous
cMyBP-C(t/t) DCM heart tissue as having prominent his-
tologic abnormalities [11]. Here, we performed histopatho-
logical evaluation of WT and DCM hearts using H&E and
Masson’s trichrome staining. H&E staining of WT and DCM
whole hearts revealed robust dilation of DCM hearts from
cMyBP-C(t/t) animals (Figure 1(f)). H&E staining of WT and
DCM myocardial sections indicated eccentric hypertrophy
and myocardial disarray in DCM hearts (Figure 1(g)). We
observed a higher tendency of cellularity in DCM hearts
quantified from H&E labeled sections (Figure 1(i)). The level
of fibrosis captured (Figure 1(h)) and quantified (Figure 1(j))
by Masson’s trichrome staining of myocardial sections from
WT and DCM hearts revealed significantly elevated fibrosis
in hearts from DCM animals compared to WT hearts. These
data indicate scar tissue development, possible cell invasion
upon cardiac remodeling, and loss of structural integrity in
DCM hearts.
3.2. SHG Imaging of DCM Hearts Depicts Loss of Cellu-
lar Structure and Myocyte Damage. Diminished fractional
shortening in DCM hearts suggested dysfunction at the level
of the sarcomere. Previous methods looking at sarcomere
structure used electron microscopy [10], limiting the cellular
area that could be imaged and preventing the observation of
other nearby defects. Therefore, we used second harmonic
generation (SHG) imaging of WT and DCM heart tissue
sections to simultaneously detect cellular structure and col-
lagen deposition. Compared to WT hearts (Figure 2(a)),
the SHG analysis indicated clear disorganization of cellular
structure in DCMhearts (Figures 2(b) and 2(c)), especially at
sites closer to the inner chamber wall where myocytes were
most damaged.WT hearts showed well-organized sarcomere
patterns in areas spanning from close to distant from the
inner wall of the chamber (Figure 2(d), left). Sites radially
away from the inner chamber were not disorganized to the
extent as near the chamber in DCM hearts (Figure 2(d),
right). This pattern of disorganization was revealed by the
forward SHG images while backward SHG images depicted
increased collagen presence (compare green channel in WT
and DCM images), indicative of fibrosis. In accordance
with this, the Fast Fourier Transformation (FFT) analysis
of sarcomere pattern integrity of the images at the sites of
damage confirmed the above inference. The disorganization
was much higher at subset areas closer to inner chamber
where the high frequency bands are completely lost in DCM
hearts (Figures 2(e), right, and 2(f), right) compared to WT
hearts (Figures 2(e), left, and 2(f), left). Loss of sarcomere pat-
tern is quantified further using line intensity profiles. Profiles
with fewer spikes indicate loss of fine structure (flat profiles).
Line intensity profiles of DCM hearts produced fewer spikes
compared to theWT hearts. This was irrespective of whether
a single line was drawn across the entire image (Figure 3(a))
as depicted by radial line intensity profiles (Figure 3(d)), or
if multiple line profiles were drawn on cell rows (Figure 3(b),
left to right) starting from the chamber to cell rows away from
the chamber (line intensity profiles in Figure 3(e), profiles
1–4). Furthermore, DCM hearts had 52% lower sarcomere
area than WT hearts (Figure 3(c)). Together, these data are
indicative of severe cardiac myocyte damage in DCM hearts.
3.3. Increased Oxidative Stress in Hearts from DCM Ani-
mals and Cardiomyopathy Patients. Mutations in sarcom-
eric proteins often generate inefficiency in contraction that
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Figure 1: DCM hearts display contractile dysfunction, fibrosis, and myocardial disarray. (a) Representative parasternal long-axis M-mode
echocardiographic images of WT and DCM hearts. Left ventricular internal diameter (LVID) is depicted by white lines (note: difference
in scale between images). LVID at (b) peak diastole and (c) peak systole in WT and DCM hearts (𝑛 = 9 hearts, ∗𝑃 < 0.001). Functional
measurements derived from LVID measurements showing (d) ejection fraction (EF) and (e) fractional shortening (FS) in WT and DCM
hearts (𝑛 = 9 hearts, ∗𝑃 < 0.001). (f) H&E labeled whole hearts from WT and DCM animals. (g) H&E or (h) Masson’s trichrome-labeled
regions of interest (ROI) from WT and DCM hearts. (i) Quantification of cellularity based on nuclear area between WT (𝑛 = 5 hearts, 5
sections per heart) and DCM hearts (𝑛 = 4 hearts, 5 sections per heart). (j) Quantification of fibrosis (trichrome staining) area between WT
(𝑛 = 4 hearts, 20 sections per heart) and DCMhearts (𝑛 = 4 hearts, 20 sections per heart; ∗𝑃 < 0.0225). Data are represented as mean ± SEM.
Significant differences (𝑃 < 0.05) between mean values were determined using Student’s 𝑡-test.
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Figure 2: Second harmonic generation (SHG) imaging demonstrates disorganized sarcomere pattern in DCM hearts. (a) The sarcomere
pattern in WT hearts closer to the inner chamber is discernible, is well-organized, and has low levels of collagen (green) (scale bar, 133𝜇m).
(b) In contrast, DCM hearts lack an organized sarcomere pattern (scale bar, 50 𝜇m). (c) High magnification (HM) image of an area in (b),
showing clear loss of sarcomeric structure in these swollen areas. Green channel is backward SHG (BSHG) depicting predominantly collagen
fibers, red channel is autofluorescence (AF), and blue channel is forward directed SHG (FSHG) showing sarcomere pattern and their merge.
(d) Fast Fourier Transformation (FFT) analysis of the sarcomere pattern in WT and DCM hearts from the inner chamber area to distal parts
of the hearts. (e) FFT of the whole frames in (d), note the fuzziness in the high frequency pattern. However, the localized changes in sarcomere
pattern could not be discerned while doing whole frame FFT analysis. (f) FFTs of regions of interest (1, 2, and 3) from the inner chamber
of heart to distal part as depicted in highlighted areas in (d) showing the region specific disorganization in sarcomeric pattern. Note there is
no difference in FFT pattern in location 3 of both WT and DCM hearts, although, in regions closer to the inner chamber (2) and especially
in swollen regions (1), there is a substantial difference in DCM hearts but there are no discernible differences in WT. Images ((a)–(d)) are
representative of multiple locations of 2 hearts (𝑛 = 2).
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Figure 3: Loss of high frequency information (bands) directly indicates loss of typical sarcomere ladder structure in DCM hearts. Sarcomere
fine structure in images from Figure 2(d) for DCM and WT heart sections is traced by drawing line intensity profiles across the cellular
structures. (a) Loss of cellular structure in DCM (right) compared to WT (left) heart sections is indicated by drawing a single line from the
inner chamber, which is (d) represented by line intensity profiles for both WT (left) and DCM (right) sections. (b) Loss of cellular structure
is further indicated by multiple line profiles drawn left to right in DCM (right) compared toWT (left) heart sections, which is (e) represented
by line intensity profiles (1–4) for bothWT (left) and DCM (right) sections. (c) Sarcomere area imaging inWT (left) and DCM (right) hearts.
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Figure 4: Increased oxidative stress in the hearts of DCM animals and cardiomyopathy patients. (a) Representative EPR spectra of CM∙
measured at room temperature. Heart tissues (50mg) were treated with CMH (1mM) in Krebs buffer containing deferoxamine mesylate
(25 𝜇M) and incubated at 37∘C in a water bath for 30 minutes. The reactive oxygen species oxidize CMH into CM∙. Blank samples are in
the absence of heart tissue. (b) Summary data of CM∙ (𝑛 = 3 hearts, ∗𝑃 < 0.034 in DCM versus WT by Student’s 𝑡-test, and blank shown
for representation). No significant accumulation of CM∙ was observed in the absence of heart tissues. (c) Comparison of GSH/GSSG ratios
(𝑛 = 6 hearts), (d) carbonyl content (𝑛 = 6 hearts), and (e) MDA and HAE content (𝑛 = 8 hearts) in WT and DCM mouse heart tissue
homogenates (∗𝑃 < 0.05). (f) Comparison of GSH/GSSG ratios, (g) carbonyl content, and (h) MDA and HAE content in donor (𝑛 = 13
hearts) and cardiomyopathy (𝑛 = 14 hearts) human heart tissue homogenates (∗𝑃 < 0.001). Data are represented as mean ± SEM. Significant
differences (𝑃 < 0.05) between mean values were determined using Student’s 𝑡-test.
cannot cope with the demand required for proper contractile
function leading to severe mechanical stress. Over time,
progressive deterioration of contractile function perpetuates
myocyte damage (Figures 2 and 3), which may stimulate
oxidative stress that aggravates the progression of cardiomy-
opathies caused by sarcomere protein mutation. Indeed,
oxidative stress has been demonstrated to be elevated in
human HCM [27] as well as DCM caused by viral infection,
inflammation, toxic substances [28], and mutation of cTnT
[10]. As we observed severe cardiac dysfunction, fibrosis,
and myocyte damage, we next determined whether oxidative
stress was elevated in the hearts of cMyBP-C(t/t) DCM mice.
ROS formation was significantly increased in the hearts of
DCM animals compared to WT animals as seen by the
increased EPR signal amplitude of CM∙ formation (Figures
4(a) and 4(b)). This was further supported by measurements
of ROS damage.
Free radical species are highly reactive and can oxidize
proteins, lipids, and DNA, which may promote the onset of
cardiovascular diseases when ROS accumulate in the heart
[29]. Reduced glutathione (GSH) is a vital scavenger of ROS
and inhibits lipid peroxidation while also playing a role in
detoxification of hydrogen peroxide by glutathione peroxi-
dases [15]. The GSH/GSSG ratio, a marker of oxidative stress
and redox status, was significantly decreased in the hearts of
DCM animals and cardiomyopathy patients (patient clinical
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Figure 5: Mitochondrial oxidative stress is augmented in the hearts of DCM animals. (a) Representative EPR spectra of heart tissue
homogenatesmeasured at 77K. Semiquinone free radicals and Fe(III) fromFe-S centers signals are seen at 𝑔 = 2.01 and𝑔 = 1.94, respectively.
EPR signal amplitude was normalized against the weight of the heart and expressed as arbitrary units per gram. (b) Normalized EPR signal
amplitude of the Fe-S centers (𝑛 = 3 hearts). (c) Normalized EPR signal amplitude of the semiquinone radical (𝑛 = 3 hearts, ∗𝑃 < 0.026).
Data are represented as mean ± SEM. Significant differences (𝑃 < 0.05) between mean values were determined using Student’s 𝑡-test.
characteristics are provided in Table 1) compared to WT
animals and human donors, respectively, signifying increased
oxidative stress (Figures 4(c) and 4(f)). Additionally, when
protein side chains such as proline, arginine, lysine, and
threonine become oxidized, carbonyl groups (aldehydes and
ketones) are produced [17]. Compared to WT animals and
human donors, carbonyl content was significantly elevated
in the hearts of DCM animals and cardiomyopathy patients,
respectively, marking increased oxidative stress in the dis-
eased hearts (Figures 4(d) and 4(g)). Lipid peroxidation also
serves as an indicator of cellular injury and oxidative stress
[30]. Compared to WT animals and human donors, MDA
and HAE content were significantly elevated in the hearts
of DCM animals and cardiomyopathy patients, respectively,
indicating increased oxidative stress (Figures 4(e) and 4(h)).
Taken together, these data validate the results of our EPR
spectra analysis and reveal increased oxidative stress in the
hearts of MYBPC3-mutated DCM animals and in the hearts
of cardiomyopathy patients.
3.4. Altered Mitochondrial Function in Cardiac Tissue from
DCM Animals. Altered redox balance within mitochon-
dria will affect electron transfer in the electron transport
chain (ETC) and leads to decreased energy production and
increased superoxide generation. Thus, the elevated ROS
observed in DCM hearts may affect mitochondrial perfor-
mance. To investigate mitochondrial performance in WT
and DCM animals, we measured both semiquinone radicals
and Fe(III) signals in heart tissue. The free radical EPR
signal seen at 𝑔 = 2.01 in the heart tissue originates from
mitochondrial semiquinone radicals (Figure 5(a)) [31]. The
peak at 𝑔 = 1.94 corresponds to Fe(III) from mitochondrial
iron-sulfur (Fe-S) centers (Figure 5(a)) [31]. In hearts from
DCMmice, the EPR signal corresponding to Fe-S centers was
lower as compared to hearts from WT mice (Figure 5(b)).
The EPR signal of semiquinone radicals was significantly
decreased in the hearts from DCM mice compared to WT
mice (Figure 5(c)). Low temperature EPR results demonstrate
that the semiquinone radicals and Fe(III) from Fe-S centers
were decreased in the hearts of DCM animals, suggesting
increased mitochondrial oxidation and reduced ETC effi-
ciency.
4. Discussion
In the present study, we have demonstrated that mutation of
theMYBPC3 gene can result in cardiac oxidative stress, which
associates with contractile dysfunction, fibrosis, andmyocyte
damage in this model of sarcomere protein-mutated car-
diomyopathy. Echocardiographic analysis of the hearts from
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cMyBP-C(t/t) mice at 3 months of age specified elevated LV
internal diameter (LVID) and reduced EF and FS (Figure 1)
confirming that these mice develop severe DCM and con-
tractile dysfunction as indicated by McConnell et al. [32]. In
accordance with these findings, we demonstrate prominent
histologic abnormalities in DCM hearts, including eccentric
hypertrophy, myocardial disarray, increased cellularity, and
a significant elevation in fibrosis compared to hearts from
WT animals (Figure 1). Here, we implement forward SHG
and FFT analyses of WT and DCM heart tissue to point out
clearly disorganized cellular patterning, sarcomere structure,
andmyocyte damage in DCMhearts (Figures 2 and 3), which
is particularly evident near the inner chamber wall in DCM
hearts. Furthermore, our backward SHG analyses distinctly
indicate elevated levels of collagen in DCM hearts. This
finding, in conjunction with our histopathological analysis of
Masson’s trichrome-stained sections, confirms severe fibrosis
in DCM hearts.
The cellular damage observed in DCM hearts produced
a complete loss of cellular structure in conjunction with
sarcomere disorganization. This is in stark contrast to the
studies reported by Plotnikov et al., which, using quantitative
SHG, showed disorganized sarcomere patterning in diseased
muscles but maintenance of cellular integrity (cell size and
morphology) [33]. The discrepancy may be due in part to
the differences between disease type and the physiologi-
cal differences between the skeletal myocytes examined by
Plotnikov et al. [33] and the cardiac myocytes used in our
analyses. Importantly, it has been suggested that sarcomeric
SHG intensity patterns depend greatly upon using fresh tissue
sections, which produce a single band when the intensity
profile of the SHG signal is along the main myofibril axis
[34]. However, the chemical stress that is produced from
tissue fixation, elevated ROS due to photoconversion, or
external application of hydrogen peroxide (H2O2) [35], a
ROS producer, may cause misalignment of myosin filaments
producing the appearance of a double-banded pattern and
sarcomere disorganization [34]. In our analysis, despite the
evident sarcomere disorganization near the inner chamber
regions of DCM hearts, this disorganization is specific to
DCM heart tissue and not the fixation process as the sar-
comeric structures in similarly fixedWT heart tissue sections
displayed a normal pattern.
In genetic cardiomyopathies, mutations within sarcom-
eric proteins often generate contractile dysfunction within
cardiomyocytes producing severe mechanical stress and
myocardial remodeling. Therefore, we propose that, over
time, progressive deterioration of cardiac pump function
perpetuates myocyte and interstitial cell damage or death
that may promote increasingly severe oxidative damage that
aggravates the disease [36, 37]. Mitochondrial respiration in
the form of oxidative phosphorylation is critical for produc-
ing sufficient levels of adenosine triphosphate (ATP) to ener-
gize cardiac pump function [38].Theperturbation/disruption
of mitochondrial respiration results in the partial reduc-
tion of oxygen to form the highly reactive oxygen species
such as superoxide radicals and hydrogen peroxide [39].
Although, in addition to mitochondrial ROS production,
ROS are produced from several intracellular sources includ-
ing NAD(P)H oxidase, xanthine oxidase, uncoupled nitric
oxide synthase, cytochrome c oxidase, and arachidonic acid
metabolism [40]. In healthy individuals, the production of
ROS is balanced with antioxidant defenses [41]. However, an
imbalance between ROS generation and antioxidant defenses
leads to oxidative stress [42]. It has been well established that
an abundance of ROS is a direct cause of oxidative stress pro-
ducing lipid peroxidation, DNA and cell membrane damage,
and the loss of cells in HF [40, 43, 44]. Indeed, oxidative
stress plays a crucial role in the pathophysiology of cardiac
remodeling and HF [40]. The implication for oxidative dam-
age and antioxidant therapy in sarcomere protein-mutated
cardiomyopathy was previously studied by Marian et al. who
tested the effects of antioxidant N-acetylcysteine (NAC), a
precursor of glutathione, on diminishing established inter-
stitial fibrosis in a mouse model of human HCM caused
by cTnT-Q92 mutation [8]. As the balance between oxi-
dants and antioxidants is important for collagen homeostasis
[45], antioxidant therapy may be beneficial in reversing or
attenuating established interstitial fibrosis. cTnT-Q92 mice
had elevated levels of myocardial MDA and 4-hydroxy-2(E)-
nonenal (4HNE), similar to what we observed in cMyBP-
C(t/t) DCM heart tissue homogenates (Figure 4(e)), which is
indicative of lipid peroxidation and oxidative damage. NAC
reduced myocardial concentrations of MDA and 4HNE as
well as fibrosis in the hearts of cTnT-Q92mice [8]. In a follow-
up study, Lombardi et al. postulated that treatment of 𝛽-
myosin heavy-chain Q403 transgenic rabbits having estab-
lished cardiac hypertrophy and preserved systolic function
with NAC could reverse cardiac hypertrophy and fibrosis
in HCM [9]. Following 12 months of NAC or placebo
treatment, transgenic rabbits in the placebo group had a
significant elevation in cardiac hypertrophy, fibrosis, and
oxidized to total glutathione ratio (GSH/GSSG + GSH) [9].
NAC treatment reversed cardiac and myocyte hypertrophy
and interstitial fibrosis, prevented cardiac dysfunction, and
restored the oxidized to total glutathione ratio in 𝛽-myosin
heavy-chainQ403 transgenic rabbits [9].Most recently, using
the cTnTR141W transgenic mouse model of DCM, Lu et al.
tested whether knockdown of CYP2E1, a cytochrome P450
enzyme that catalyzes the metabolism of toxic substrates,
could inhibit oxidative stress and apoptosis of myocytes to
prevent DCM development [10]. cTnTR141W mice exhibited
increased left ventricular chamber diameter, interstitial fibro-
sis, swollenmitochondria, and poorly organizedmyofibrils as
well as elevated levels of myocardial MDA and a reduction
in GSH, suggesting augmented myocardial oxidative stress
[10]. KnockdownofCYP2E1 improved interstitial fibrosis and
myofibrillar structure and decreased myocardial oxidative
stress and apoptosis in cTnTR141W DCM mice [10]. Similar
to these reports, we observed significantly elevated fibrosis
(Figures 1(h) and 1(j)), collagen deposition (Figures 2(b) and
2(c)), carbonyl content (Figure 4(d)), andMDAandHAE lev-
els (Figure 4(e)) as well as a reduction in the GSH/GSSG ratio
(Figure 4(c)) in cMyBP-C(t/t) DCM hearts and in heart tissue
homogenates from cardiomyopathy patients (Figures 4(f)–
4(h)), signifying increased myocardial damage and oxidative
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stress. Importantly, future studies using antioxidant therapy
in cMyBP-C(t/t) DCM mice or knockdown/downregulation
of ROS generators such as CYP2E1 may lead to a reduction
in interstitial fibrosis and myocardial remodeling and could
improve cardiac function. This would suggest a therapeutic
avenue for the treatment of cardiomyopathies caused by
mutation ofMYBPC3 and other contractile proteins.
Previously, to establish direct evidence for increased ROS
in failing myocardial tissue, Ide et al. induced HF in adult
mongrel dogs by ventricular pacing [46]. EPR spectroscopy
was implemented to determine ROS production using freeze-
clamped myocardial tissue homogenates that were reacted
with the nitroxide radical, 4-hydroxy-2,2,6,6,-tetramethyl-
piperidine-N-oxyl, followed by detection of spin signals.
In HF samples, a significant increase in hydroxyl radicals,
as evidenced by the rate of electron spin resonance signal
decay, was detected providing direct evidence for enhanced
generation of ROS within the failing myocardium [40, 46].
Using this technique, our EPR spectroscopy using spin probe
CMH (Figures 4(a) and 4(b)) demonstrated that oxidative
stress is increased in the hearts of cMyBP-C(t/t)DCManimals.
This result supports our biochemical measurements and the
notion that oxidative stress plays a role in cardiac damage and
dysfunction in various forms of HF including cardiomyopa-
thy.
As described above, small quantities of mitochondrial
ROS are produced in the ETC during mitochondrial respi-
ration, which are typically detoxified by scavenging systems.
Previously, Ide et al. demonstrated that inhibiting the ETC
at complex I and complex III in normal submitochondrial
particles led to a significant elevation in superoxide anion
production as measured by EPR spectroscopy with the spin
trapping agent 5,5󸀠-dimethyl-1-pyrroline-N-oxide [47]. In
the presence of NADH, mitochondria from failing canine
hearts producedmore superoxide anions and were associated
with a reduction in complex enzyme activity suggesting
mitochondria as an important source of ROS in HF [40, 47].
In addition to their role in cellular respiration, mitochondria
are the cellular center for iron homeostasis where iron is used
for the biosynthesis of heme and Fe-S clusters [48]. Although,
when in excess, labile iron may produce highly reactive
oxygen species by the Fenton reaction inducing oxidative
damage to cardiomyocytes and myocardial injury [49], thus,
regulation of iron homeostasis is critical for cellular via-
bility. Here, EPR spectroscopy revealed a decrease in both
semiquinone radicals and Fe(III) from Fe-S centers in DCM
animals (Figures 5(a)–5(c)). The decreased EPR signal for
semiquinone radicals indicates alterations in mitochondrial
respiration [31]. The decreased EPR signal for Fe(III) from
Fe-S centers suggests alterations in the iron homeostasis
in mitochondria [31]. These results indicate that mitochon-
drial function is disturbed in the hearts of DCM animals.
Together, our EPR studies demonstrate that the impaired
mitochondrial respiration and alterations in iron homeostasis
are related to increased oxidative stress in the hearts of DCM
animals. These data suggest that alteration of normal cardiac
mitochondrial function and increased oxidative stress may
contribute to the development of cardiomyopathies caused by
sarcomere protein mutation.
In this study, we confirm that oxidative stress is elevated
at severe HF in amousemodel of sarcomere protein-mutated
cardiomyopathy caused by MYBPC3 mutation. As cMyBP-
C is heavily mutated in human cardiomyopathy, determin-
ing the mechanisms that contribute to disease progression
in cardiomyopathies caused by MYBPC3 mutations and
other sarcomere gene mutations is of critical importance.
Currently, medical therapies for HF include suppressing
neurohormonal activation and treating fluid volumeoverload
and depressed hemodynamic status. While these pharma-
cological therapies may improve symptoms and slow the
progression of contractile dysfunction, patient prognosis
remains poor. Thus, the need for novel therapies directly
targeting the factors that perpetuate disease is required
to improve cardiac performance and slow or prevent the
progression of LV dysfunction and remodeling. Therefore,
therapeutic strategies aimed at attenuating oxidative stress
could represent a novel treatment avenue to forestall the
development of cardiomyopathy in these patients. As such,
our future efforts will focus on defining the molecular redox
signaling targets for therapeutic intervention to slow the
progression of these genetic cardiomyopathies.
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